AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,418.00GBp
22 Aug 2014
Price Change (% chg)

6.50p (+0.15%)
Prev Close
4,411.50p
Open
4,423.50p
Day's High
4,450.00p
Day's Low
4,398.00p
Volume
1,779,670
Avg. Vol
2,276,779
52-wk High
4,946.41p
52-wk Low
3,085.21p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.36
Market Cap (Mil.): £55,781.16
Shares Outstanding (Mil.): 1,262.59
Dividend: 53.10
Yield (%): 3.85

Financials

  AZN.L Industry Sector
P/E (TTM): 45.63 33.74 34.44
EPS (TTM): 0.97 -- --
ROI: 5.03 18.86 18.11
ROE: 8.94 19.48 18.84
Search Stocks

Lilly psoriasis drug impresses; battle nears with Amgen, Novartis

- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

21 Aug 2014

UPDATE 2-Lilly psoriasis drug impresses; battle nears with Amgen, Novartis

(Adds details on drug, rival drugs, new treatment approach)

21 Aug 2014

Healthcare stocks lift UK's FTSE 100

* FTSE 100 up 0.3 pct, near 3-week high * AstraZeneca up on speculation over new Pfizer bid * Building supplies group CRH boosted by analyst upgrade * Miners lag after weak Chinese data By Tricia Wright and Sudip Kar-Gupta LONDON, Aug 21 - Britain's top equity index rose on Thursday on gains in healthcare stocks, led by AstraZeneca on speculation rejected U.S. suitor Pfizer might make another bid. AstraZeneca rose 3 percent while domestic rival GlaxoSmithKline

21 Aug 2014

Healthcare stocks lift UK's FTSE 100

* FTSE 100 up 0.2 pct, near 3-week high * AstraZeneca up on speculation over new Pfizer bid * Miners lag after weak Chinese data By Tricia Wright and Sudip Kar-Gupta LONDON, Aug 21 - Britain's top equity index rose on Thursday on gains in healthcare stocks, led by AstraZeneca on speculation rejected U.S. suitor Pfizer might make another bid. AstraZeneca rose 2.7 percent while domestic rival GlaxoSmithKline advanced 1 percent, adding the most points to the FTSE 100

21 Aug 2014

Pfizer back for AstraZeneca? Year-end move seen most likely

LONDON - Shares in drugmaker AstraZeneca have climbed more than 7 percent this week, fueled by speculation of renewed takeover interest from Pfizer, following an abortive $118 billion (71 billion pounds) takeover attempt in May.

21 Aug 2014

Healthcare stocks lift UK's FTSE 100

* FTSE 100 up 0.3 pct, near 3-week high * AstraZeneca up on speculation over new Pfizer bid * Miners lag after weak Chinese data By Tricia Wright and Sudip Kar-Gupta LONDON, Aug 21 - Britain's top equity index rose on Thursday on gains in healthcare stocks, led by AstraZeneca on speculation rejected U.S. suitor Pfizer might make another bid. AstraZeneca rose 2.3 percent while domestic rival GlaxoSmithKline advanced by 1.4 percent, adding the most points to the FTS

21 Aug 2014

Healthcare stocks lift UK's FTSE 100

* FTSE 100 up 0.2 pct, near 3-week high * AstraZeneca up on speculation over new Pfizer bid * Miners lag after weak Chinese data By Sudip Kar-Gupta LONDON, Aug 21 - Britain's top equity index rose on Thursday on gains in healthcare stocks, led by AstraZeneca on speculation rejected U.S. suitor Pfizer might make another bid. The blue-chip FTSE 100 index was up by 0.2 percent, or 10.83 points, at 6,766.31 points in early trading, approaching three-week highs touched

21 Aug 2014

AstraZeneca and Mitsubishi Tanabe link on diabetes research

LONDON - AstraZeneca and Mitsubishi Tanabe Pharma said on Wednesday they said signed a three-year research collaboration into diabetic nephropathy, or kidney failure due to diabetes.

20 Aug 2014

AstraZeneca and Mitsubishi Tanabe link on diabetes research

LONDON, Aug 20 - AstraZeneca and Mitsubishi Tanabe Pharma said on Wednesday they said signed a three-year research collaboration into diabetic nephropathy, or kidney failure due to diabetes.

20 Aug 2014

U.S. clears AstraZeneca over heart drug trial

LONDON - The U.S. government has cleared AstraZeneca Plc over a major clinical trial used to win marketing approval for its important new heart drug Brilinta, following an investigation which had cast a shadow over its prospects.

19 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks